Sensus Healthcare (NASDAQ:SRTS) Issues Earnings Results, Misses Estimates By $0.04 EPS

by · The Cerbat Gem

Sensus Healthcare (NASDAQ:SRTS – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04), Zacks reports. The firm had revenue of $3.39 million for the quarter, compared to analysts’ expectations of $5.32 million. Sensus Healthcare had a negative net margin of 28.09% and a negative return on equity of 15.11%.

Here are the key takeaways from Sensus Healthcare’s conference call:

  • Sensus says new dedicated CPT codes effective Jan 1, 2026 materially improve reimbursement — including about a 300% increase in the per‑fraction delivery code — and early EOBs show payers are processing claims, which management says is driving stronger physician interest and pipeline growth.
  • Q1 revenue was $3.4 million versus $8.3 million a year ago primarily because there were no sales to the company’s historically largest customer; adjusted EBITDA was negative $4.2 million and net loss was $2.6 million, though management notes underlying growth when excluding that customer.
  • Management is prioritizing recurring revenue through the Sensus Link software and the Fair Deal/rental program (18 active Fair Deal sites, 9 pending), and highlighted a reimbursable weekly radiation physics code (~$93.85/week) that can be monetized and shared with customers via Sensus Link.
  • Commercial expansion initiatives — 14 systems shipped in Q1 (10 direct, 4 Fair Deal/rental), ~70% purchases of systems in the quarter, the launch of Sensus Healthcare Financial Services, and a stronger conference-driven pipeline — underpin management’s expectation of higher Q2/H2 revenue and a path to full‑year profitability.

Sensus Healthcare Trading Down 25.1%

SRTS stock traded down $1.03 during trading on Friday, reaching $3.08. The stock had a trading volume of 665,134 shares, compared to its average volume of 84,977. Sensus Healthcare has a 1-year low of $2.82 and a 1-year high of $5.92. The company has a market capitalization of $50.70 million, a P/E ratio of -6.55 and a beta of 1.19. The firm has a fifty day moving average price of $4.14 and a 200 day moving average price of $4.16.

Analysts Set New Price Targets

SRTS has been the topic of several research analyst reports. Maxim Group reduced their price objective on Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Alliance Global Partners assumed coverage on shares of Sensus Healthcare in a research report on Friday, March 6th. They set a “buy” rating and a $7.50 target price for the company. Wall Street Zen lowered shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Citigroup reaffirmed a “buy” rating on shares of Sensus Healthcare in a research report on Friday. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Sensus Healthcare in a research note on Tuesday, April 21st. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sensus Healthcare presently has a consensus rating of “Moderate Buy” and an average target price of $6.88.

View Our Latest Research Report on Sensus Healthcare

Institutional Trading of Sensus Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the business. XTX Topco Ltd acquired a new position in shares of Sensus Healthcare in the fourth quarter worth about $77,000. Rothschild Wealth LLC purchased a new position in Sensus Healthcare in the fourth quarter valued at about $500,000. Greenline Wealth Management LLC acquired a new stake in Sensus Healthcare during the 4th quarter valued at approximately $513,000. Ingalls & Snyder LLC acquired a new stake in Sensus Healthcare during the 4th quarter valued at approximately $219,000. Finally, State Street Corp increased its holdings in Sensus Healthcare by 5.2% during the 4th quarter. State Street Corp now owns 69,252 shares of the company’s stock worth $276,000 after purchasing an additional 3,400 shares during the last quarter. 25.30% of the stock is owned by hedge funds and other institutional investors.

About Sensus Healthcare

(Get Free Report)

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.

See Also